Study identifier:NIS-ODE-ARI-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Arimidex: Compliance and arthralgias in clinical therapy (COMPACT): An in practice assessment of arthralgias and related costs as well as compliance in the first year of anastrozole therapy
Breast Cancer
-
No
-
Female
2313
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Patients are eligible for inclusion in this NIS if they have taken anastrozole either upfront or following two to three years of tamoxifen treatment (“switch”) for at least three and not more than six months prior to offering an individual participation in this program. Treatment should follow local therapy guidelines and standard practice. Treatment decisions for patients participating in this study including assessments or supportive therapy during follow-up visits will also follow guidelines and remain independent of the program.
The patient population will include postmenopausal women with hormone-receptor positive primary breast cancer scheduled for adjuvant upfront endocrine treatment with anastrozole or following two to three years of tamoxifen treatment (“switch”) according to the current SmPC (Appendix C). Patients will have taken anastrozole for at least three months and not more than six months before the start of the study.
Location
Location
Aachen, Germany, Germany
Location
Aalen, Germany, Germany
Location
Ahaus, Germany, Germany
Location
Albstadt, Germany, Germany
Location
Altotting, Germany, Germany
Location
Alzey, Germany, Germany
Location
Amberg, Germany, Germany
Location
Apolda, Germany, Germany
Arms | Assigned Interventions |
---|---|
All patients treated with Anastrozole as per SPC | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.